Dartmouth’s Riley Ennis and his award-winning research and start-up bio-tech company are featured on a FoxNews “Solution America” episode focusing on bright young scientists and entrepreneurs who are working to solve problems “big and small.” Ennis has developed a vaccine to help the body use its own immune system to fight cancer cells. He is CEO of his own company, Immudicon, which he founded to get the attention of major bio-technology firms that would make the vaccine available to people as soon as possible.
One Dartmouth College freshman is on track to cure cancer with a vaccine – spending hours a day on the project, on top of schoolwork. Riley Ennis, 18, started his research at just 15 years old. This young entrepreneur, now marketing his findings, believes he may have found a way to teach our bodies to fight other diseases as well. “Forty years ago, Nixon declared war on cancer,” Ennis said, citing not much has changed in how the disease is treated through techniques like chemotherapy and radiation.
I am continuously amazed when I hear about young scientists – high school students - who are making a difference in the future of medicine. I recently talked with Riley Ennis, a freshman at Dartmouth College, who won the Virginia BioGENEius Challenge last year and went on to become a U.S. National BioGENEius finalist. He started developing a new way to treat cancer while he was still in high school. Read on to find out about this young man's journey and the role the Virginia BioGENEius Challenge has played in his life.
The Chesapeake Bioscience Education Foundation (C-BEF), today announced the names of the three winners of the 2011 Virginia BioGENEius Challenge, co-sponsored by the Virginia Biotechnology Association (VABIO). The Challenge is a rigorous, statewide competition among high school biology students from across the Commonwealth. The students will now advance to the U.S. National BioGENEius Challenge and have a chance to compete at the International BioGENEius Challenge competition, which will be held June 27, at the 2011 Biotechnology Industry Organization (BIO) International Convention in Washington, D.C.